Title: Clinical comparison study on pemetrexed combined with carboplatin versus paclitaxel combined with carboplatin as concurrent chemoradiotherapy in locally advanced non-small cell lung cancer
Abstract: Objective To observe the effect and clinical toxicity of pemetrexed combined with carboplatin versus paclitaxel combined with carboplatin with concurrent chemoradiotherapy in locally advanced non-small cell lung cancer (NSCLC).Methods Total of 60 patients stage Ⅲ NSCLC (ⅢA 39 patients,ⅢB 21 patients) were randomly assigned into two groups.Pemetrexed combined with carboplatin group:accepted pemetrexed 500 mg/m2,d1,carboplatin AUC 5,d1,once every 21 days.Paclitaxel combined with carboplatin group:paclitaxel 150 mg/m2,d1,carboplatin AUC 5,d1,once every 21 days.Two groups both accepted 3-D conformal radiation therapy (3D-CRT) during chemotherapy.The total dose was 60 ~ 70 Gy.After radiation therapy,the patients were accepted 2 ~ 3 cycles of chemotherapy.Results The efficacy of pemetrexed combined with carboplatin and paclitaxel combined with carboplatin were 44.83% and 29.03% respectively.The disease control rates of two groups were 79.31% and 67.74% respectively.The differences were statistically significant (P<0.05).The adverse reactions of pemetrexed group were rare.Two groups of median progression-free survival were 12.5 and 9.9 months respectively.1 year overall survival was 58.62% and 48.39% respectively.The differences were also significant (P<0.05).Conclusion Pemetrexed combined with carboplatin can be used as stage Ⅲ NSCLC patients treated with concurrent chemoradiation regimens during optimization.Toxicity was tolerable.Pemetrexed group was better than paclitaxel group in disease control rates and survival.
Key words:
Pemetrexed; Paclitaxel; Concurrent chemoradiotherapy; Non-small cell lung cancer
Publication Year: 2013
Publication Date: 2013-08-15
Language: en
Type: article
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot